Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Theravance and Astellas Announce FDA Approval of VIBATIV(TM) (telavancin) for the Treatment of Complicated Skin and Skin Structure Infections
Theravance and Astellas Announce FDA Approval of VIBATIV(TM) (telavancin) for the Treatment of Complicated Skin and Skin Structure Infections
Theravance and Astellas Announce FDA Approval of VIBATIV(TM) (telavancin) for the Treatment of Complicated Skin and Skin Structure Infections
Submitted by
admin
on September 12, 2009 - 10:31am
Source:
MarketWire
News Tags:
Theravance
Astellas
Vibativ
Headline:
Theravance and Astellas Announce FDA Approval of VIBATIV(TM) (telavancin) for the Treatment of Complicated Skin and Skin Structure Infections
Do Not Allow Advertisers to Use My Personal information
